Islet cell transplantation can functionally cure type 1 diabetes and also improve carotid intima-media thickness. This study provides a preliminary description of changes in coronary artery calcium following islet transplantation, and associated factors. statin dose (P = .02), and urine albumin-to-creatinine ratio (P = .04) and negatively associated with free fatty acids (P = .03), total HDL (P = .03), large HDL particles (P = .005), and tacrolimus dose (P = .02). Islet transplant may stabilize coronary artery calcium, with optimal management of lipids and kidney function remaining key therapeutic targets. [NCT00679041].
| INTRODUCTION
Cardiovascular disease (CVD) is the main cause of morbidity and mortality among individuals with type 1 diabetes. 1, 2 Epidemiologic studies have demonstrated that after 20 years duration of type 1 diabetes, over 40% of deaths are attributable to CVD. 2 Despite the beneficial effects of intensive insulin therapy on reducing the risk of CVD events in recent decades, 3 compared to men and women without type 1 diabetes, having type 1 diabetes is still associated with fourfold and eightfold increased risk for CVD events in men and women, respectively. 1 The increased risk of death from CVD is even higher in women who were diagnosed with type 1 diabetes before or during puberty.
Coronary artery calcium (CAC), a marker of atherosclerotic plaque, can be measured using electron-beam tomography (EBT), a highly sensitive non-invasive method. 4 Coronary artery calcium is used to screen for CVD and can predict future fatal and non-fatal cardiovascular events across all levels of CVD risk, 5 particularly in asymptomatic intermediate-risk persons. 6 The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study showed type 1 diabetes is associated with higher CAC prevalence in both sexes across all ages compared to people without diabetes. 7 The Epidemiology of Diabetes Interventions and Complications (EDIC) study measured CAC 7-9 years after the close of the Diabetes Control and Complications Trial (DCCT) and found the intensive treatment group had lower average CAC scores and lower prevalence of CAC > 0 compared to the conventional treatment group. 8 However, it is unknown how useful CAC is in predicting CVD risk in patients with type 1 diabetes. Greater progression of CAC in type 1 diabetes has been associated with poor glycemic control, 9 impaired kidney function, 10 inflammation, 11 and insulin resistance. 7 Islet cell transplantation is an experimental therapy that provides a potential functional cure for patients with type 1 diabetes who experience hypoglycemic unawareness despite optimal insulin therapy. 12 Islet cells from deceased human donors are isolated, purified, then infused through the recipient's portal vein to engraft into the liver, reestablishing endogenous insulin secretion; one to three transplants are performed to establish/maintain glycemic control. 13 Multiple improvements in islet transplant outcomes have been achieved over the last decade, 14 allowing patients with type 1 diabetes to achieve insulin independence and essentially eliminate hypoglycemic events. 13, 15 Regarding cardiovascular health, islet cell transplantation has also been shown to improve the function of circulating angiogenic cells involved in vascular repair, 16 and significantly reduce carotid intimamedia thickness (CIMT), a marker of atherosclerosis, within 1 year following transplant. 17 Despite these benefits, the effect of islet transplant on other markers of CVD is not clear, and additional research is needed to understand the impact on cardiovascular health, particularly given the negative effects immunosuppression can have on blood pressure and lipid levels. 18, 19 Serial cardiac EBT may allow monitoring of cardiovascular risk by quantifying CAC before and after islet cell transplantation, which to the best of our knowledge has not been done. We therefore describe changes in CAC over time in patients with long-standing type 1 diabetes following islet transplant, and provide a preliminary analysis of factors associated with change in CAC in the University of Illinois at Chicago's (UIC's) phase 1/2 and 3 islet transplant clinical trials. We hypothesized that CAC would either regress or stabilize (similar to CIMT) following transplant, and that these changes in CAC would be associated with beneficial changes in factors such as inflammation, lipid levels, blood pressure, and glycemic control after islet transplantation.
| MATERIALS AND METHODS

| Study participants
The current study includes the first 14 patients enrolled in UIC's phase 1/2 (n = 10) and phase 3 (n = 4) clinical trials (NCT00679042) of allogeneic pancreatic islet transplant, who also had data available on CAC. The trials have been previously described. 13 
| Measurement of CAC (dependent variable)
All 14 patients underwent EBT pre-transplant, with the 11 transplanted patients receiving subsequent scans approximately every 12-18 months post-transplant at the UIC Medical Center. Measurement of CAC was performed according to the UIC scanning protocol as previously described. 21 Briefly, images were obtained using a GE Imatron computed tomography scanner (GE Imatron, San Francisco, CA, USA).
CAC volume was calculated individually for the left main, left anterior descending, circumflex, and right coronary arteries using isotropic interpolation, 22 then summed to produce a total CAC volume score.
A published population-based estimate of the prevalence of CAC progression in people with type 1 diabetes not receiving islet transplant, but similar to our sample (CACTI), was used for comparison. 23 Three islet transplant patients received one CAC scan, six patients received two scans, three patients received three scans, and two patients received four scans across 1 to 4 years following their first islet transplant.
| Clinical measurements (independent variables)
Patient characteristics included age and duration of type 1 diabetes at first transplant, sex, history of smoking, and timing of CAC measure- 
| Statistical analysis
Data from 32 serial EBT scans were available. The data were analyzed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at P < .05. The distribution of variables was assessed and transformed if skewed. Means and standard deviations (SDs) were calculated for continuous variables, and frequencies and percentages for categorical variables, both at baseline and over follow-up. Scatter plots were used to examine associations between the dependent and independent variables and to identify outliers. One abdominal fat observation was an extremely influential outlier, so was replaced with the value from the prior EBT scan.
Coronary artery calcium volume score, the primary dependent variable, was highly variable and positively skewed. Coronary artery calcium volume score was square-root transformed to normalize the distribution of the residuals and stabilize interscan variation across repeated measurements. 25 Coronary artery calcium progression or regression was defined as a ≥ 2.5 unit change 25 (increase or decrease, respectively) in the square-root transformed CAC volume score from baseline to last follow-up assessment. The proportion for progression was compared to a reference type 1 diabetes sample (CACTI) using
Fisher's exact test. (Table 1B) . Baseline and mean change across follow-up for clinical measures and laboratories within these 11 patients are shown in Table 2 . Patients experienced decreases in HbA 1c
| RESULTS
and in all measures of adiposity, including SAT and TAT, following islet transplant. Increases were seen in blood pressure but also HDL, with an increase in kidney damage (increase in urine albumin-to-creatinine ratio), although kidney function (ie, eGFR) did not change.
| CAC outcomes
More than half (57%) of the 14 patients had detectable CAC at baseline; the mean (SD) baseline CAC volume score (square-root transformed) was 8.7 (11.1) mm 3 , ranging from 0 to 32.6 mm 3 (Table 1) .
T (9) years and 24 (9) years, but slightly higher BMI (~26) and HbA1c (~8%), 23 islet transplant recipients trended toward less progression, although it did not reach statistical significance (19% vs 0%, P = .22).
| Associations with CAC
Individual models of factors associated with the slope of change in CAC volume score, adjusted for confounding by baseline CAC volume score, adiposity, and transplanted IEQs/kilogram, are presented in Table 3 . Increasing CAC levels were associated with increases in total VLDL particles, particularly small VLDL particles, following transplant.
Increasing CAC was also associated with both a higher statin daily dose and a higher urine albumin-to-creatinine ratio after transplant.
Decreases in CAC were associated with higher HDL levels, particularly the large HDL particles, and FFAs following transplant. A higher tacrolimus dose was also associated with a decrease in CAC over time.
Further adjustment by other covariates (eg, adjusting HDL levels for statin use) did not change these results, nor did excluding the one male 
| DISCUSSION
To the best of our knowledge, this study was the first to describe changes in CAC following islet transplant, and to provide a prelimi- diabetes without known heart disease. 27 However, future research is needed to confirm our findings and to determine clinical significance.
Increasing CAC after transplant was associated with several factors, mainly related to atherogenic lipoproteins, increasing kidney damage, and a lower tacrolimus dose. Hyperlipidemia is a well-established contributor to atherosclerosis, particularly in type 1 diabetes, 28 that may be exacerbated in islet transplant recipients by certain F I G U R E 1 Individual patients' coronary artery calcium (CAC) volume scores (square-root transformed) before and after transplant (n = 11). Squares represent initial and subsequent islet cell transplants received during the follow-up period. Color coded per individual patient. (Inset) Change in individual patients' CAC volume scores (square-root transformed) before and after transplant (n = 11) immunosuppressive drugs. 18, 19 The positive association between a higher statin dose following transplant and greater CAC in our patients likely reflects the higher lipid levels associated with CAC following transplant that require more aggressive treatment. The significant positive association between VLDL particle level and CAC observed in our study is consistent with a previous study of men and women with type 1 diabetes taken from type 1 diabetes registers in London 29 ;
however, that study did not find an association with small VLDL particles and CAC, whereas the current study did. Cardiovascular and renal complications in type 1 diabetes are closely related, and a higher albumin excretion ratio is a known risk factor for CVD in those with type 1 diabetes. 28 The demonstrated relationship between increasing kidney damage and increasing CAC following transplant is similar to findings by the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study that observed albumin excretion rate to be a predictor of CAC progression in patients with type 1 diabetes. 30 Kidney function and damage may be negatively impacted by both tacrolimus 31 and sirolimus, 32 respectively, which were taken by all patients in our study.
However adjusting for immunosuppressive medication class did not change the significant association between CAC and kidney damage after transplant.
A limited number of studies 33 and adiposity 7, 9, 40 ; however, our study found no association between either adiponectin or inflammatory markers and CAC. Also, despite overall decreases in weight and all measures of abdominal adiposity across follow-up, we did not observe any association between adiposity and CAC.
Therefore, while some predictors of CAC progression were similar between patients living with type 1 diabetes and those functionally cured after islet transplant, significant predictors also differed.
Given these differences, it is important to note that the clinical trial exclusion criteria resulted in relatively healthy patients with normal
BMIs, fairly good glycemic control, well-controlled cholesterol and blood pressure, and without active cardiovascular disease at study enrollment. One patient however did have a prior history of cardiac stenting (outside of the 6 month window prior to study enrollment), but remained asymptomatic during the study. In addition, almost half our cohort (43%) had a history of smoking, with the two patients with the highest baseline calcification (Figure 1 ) each having smoked for more than 20 years. Despite this, the islet transplant patients overall appeared to be a more select group than people living with type 1 diabetes participating in population-based studies.
Review of the UIC islet transplant patients enrolled in 5-and 10-year follow-up shows that no patients have experienced any major cardiovascular events (eg, stroke, myocardial infarction) since their last EBT scan, with just one, a former smoker, requiring coronary stents to date.
A strength of this study was the prospective design consisting of pre-transplant and longitudinal measures of both the dependent and independent variables. This allowed the assessment of changes in CAC following intervention, in this case islet transplantation.
Additionally, CAC was measured more than once after transplant in the majority of patients, allowing the assessment of change in CAC over time. The nature of the inclusion/exclusion criteria for the study provided a study sample that was free from active cardiovascular disease at baseline. A limitation of the current study is the small number of patients in whom CAC was measured. Of the 14 participants with baseline EBT scans, 11 received additional CAC imaging following transplant, resulting in 32 observations for analysis. Islet transplant clinical trials are not powered for robust analysis of diabetes complications, but instead for safety and efficacy. 41 Also, given the current experimental nature of islet cell transplant as a treatment for a select subgroup with type 1 diabetes, larger numbers of participants
are not yet available. Therefore, this study provides an exploratory analysis of CAC in this patient population, where associations with statistical significance P < .05 may be considered associations of interest for future research. As has been previously described by the Food and Drug Administration, there are no control groups in islet cell transplant clinical trials because of the inability to blind patients/ investigators, as well as the unwillingness of patients to be assigned to a control group. 41 However, this might be seen as a limitation, so a control group from the literature was used. It is also considered unethical to randomize these patients to either islet transplant or an alternative treatment for hypoglycemic unawareness purely for research reasons, because in order to be eligible for islet transplantation, they would have already tried and failed such existing treatments. 42 Additional limitations include the participant sample was composed of mostly female patients, limiting the generalizability of findings, and information such as patients' dietary and physical activity behaviors were not available.
In conclusion, the current study describes potential stabilization of CAC in patients with type 1 diabetes that were functionally cured 
